RJA
TEVA icon

Raymond James & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Raymond James & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,900
Closed -$25K – 3715
2018
Q2 		$25K Buy
+10,900
New +$222K ﹤0.01% 3487

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Raymond James & Associates's TEVA Position: Q3 2024 in Review

Raymond James & Associates increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q3 2024, buying an estimated $3.58M and bringing the position to 1,020,719 shares worth $18.4M. The position accounts for 0.01% of the portfolio, ranked #859.

Raymond James & Associates first reported a position in TEVA in Q2 2013 and has held it in 46 quarters since. The position peaked at $28M in Q2 2015. 543 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Raymond James & Associates held 1,020,719 shares of Teva Pharmaceuticals worth $18.4M as of Q3 2024.
  • Raymond James & Associates bought 204,775 Teva Pharmaceuticals shares in Q3 2024, an estimated $3.58M.
  • Teva Pharmaceuticals made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #859 holding.
  • Raymond James & Associates first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 46 quarters since.
  • Raymond James & Associates's Teva Pharmaceuticals position peaked at $28M in Q2 2015.
  • 543 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.